Medicaid Utilization and Gross Spending on New Drugs Used for Weight Loss has Increased Rapidly in Recent Years

Number of Medicaid Outpatient Prescriptions for GLP-1 Agonists (Ozempic, Rybelsus, Wegovy, and Mounjaro) by Year

Number of Prescriptions   Gross Spending  

NOTE: GLP-1 = glucagon-like peptide-1. Gross spending is Medicaid spending before rebates. State Medicaid coverage of drugs approved for weight-loss (Wegovy in this analysis) is limited, but Ozempic, Rybelsus, and Mounjaro are approved to treat type 2 diabetes and covered by Medicaid in all states for that label indication. SOURCE: KFF analysis of 2019-2022 State Drug Utilization Data, accessed August 2023.
KFF.org (grey border)